Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

A phase 3 trial of IV immunoglobulin for Alzheimer disease.

Relkin NR, Thomas RG, Rissman RA, Brewer JB, Rafii MS, van Dyck CH, Jack CR, Sano M, Knopman DS, Raman R, Szabo P, Gelmont DM, Fritsch S, Aisen PS; Alzheimer's Disease Cooperative Study.

Neurology. 2017 May 2;88(18):1768-1775. doi: 10.1212/WNL.0000000000003904. Epub 2017 Apr 5.

2.

Effective anti-Alzheimer Aβ therapy involves depletion of specific Aβ oligomer subtypes.

Knight EM, Kim SH, Kottwitz JC, Hatami A, Albay R, Suzuki A, Lublin A, Alberini CM, Klein WL, Szabo P, Relkin NR, Ehrlich M, Glabe CG, Gandy S, Steele JW.

Neurol Neuroimmunol Neuroinflamm. 2016 May 10;3(3):e237. doi: 10.1212/NXI.0000000000000237. eCollection 2016 Jun.

3.

Two Novel Psychomotor Tasks in Idiopathic Normal Pressure Hydrocephalus.

Rossetti MA, Piryatinsky I, Ahmed FS, Klinge PM, Relkin NR, Salloway S, Ravdin LD, Brenner E, Malloy PF, Levin BE, Broggi M, Gavett R, Maniscalco JS, Katzen H.

J Int Neuropsychol Soc. 2016 Mar;22(3):341-9. doi: 10.1017/S1355617715001125. Epub 2016 Jan 28.

PMID:
26817685
4.

An update on research priorities in hydrocephalus: overview of the third National Institutes of Health-sponsored symposium "Opportunities for Hydrocephalus Research: Pathways to Better Outcomes".

McAllister JP 2nd, Williams MA, Walker ML, Kestle JR, Relkin NR, Anderson AM, Gross PH, Browd SR; Hydrocephalus Symposium Expert Panel.

J Neurosurg. 2015 Dec;123(6):1427-38. doi: 10.3171/2014.12.JNS132352. Epub 2015 Jun 19.

PMID:
26090833
5.

A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease.

Green RC, Christensen KD, Cupples LA, Relkin NR, Whitehouse PJ, Royal CD, Obisesan TO, Cook-Deegan R, Linnenbringer E, Butson MB, Fasaye GA, Levinson E, Roberts JS; REVEAL Study Group.

Alzheimers Dement. 2015 Oct;11(10):1222-30. doi: 10.1016/j.jalz.2014.10.014. Epub 2014 Dec 9.

6.

Amyloid-ß-directed immunotherapy for Alzheimer's disease.

Lannfelt L, Relkin NR, Siemers ER.

J Intern Med. 2014 Mar;275(3):284-95. doi: 10.1111/joim.12168. Review. Erratum in: J Intern Med. 2014 May;275(5):546.

7.

Diagnosis and management of idiopathic normal-pressure hydrocephalus.

Williams MA, Relkin NR.

Neurol Clin Pract. 2013 Oct;3(5):375-385.

8.

Influence of comorbidities in idiopathic normal pressure hydrocephalus - research and clinical care. A report of the ISHCSF task force on comorbidities in INPH.

Malm J, Graff-Radford NR, Ishikawa M, Kristensen B, Leinonen V, Mori E, Owler BK, Tullberg M, Williams MA, Relkin NR.

Fluids Barriers CNS. 2013 Jun 10;10(1):22. doi: 10.1186/2045-8118-10-22.

9.

Alzheimer's disease and Down's syndrome: treating two paths to dementia.

Weksler ME, Szabo P, Relkin NR, Reidenberg MM, Weksler BB, Coppus AM.

Autoimmun Rev. 2013 Apr;12(6):670-3. doi: 10.1016/j.autrev.2012.10.013. Epub 2012 Nov 29. Review.

PMID:
23201920
10.

Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model.

Steele JW, Lachenmayer ML, Ju S, Stock A, Liken J, Kim SH, Delgado LM, Alfaro IE, Bernales S, Verdile G, Bharadwaj P, Gupta V, Barr R, Friss A, Dolios G, Wang R, Ringe D, Fraser P, Westaway D, St George-Hyslop PH, Szabo P, Relkin NR, Buxbaum JD, Glabe CG, Protter AA, Martins RN, Ehrlich ME, Petsko GA, Yue Z, Gandy S.

Mol Psychiatry. 2013 Aug;18(8):889-97. doi: 10.1038/mp.2012.106. Epub 2012 Jul 31.

11.

Longitudinal analysis of novel Alzheimer's disease proteomic cerebrospinal fluid biomarkers during intravenous immunoglobulin therapy.

Shayan G, Adamiak B, Relkin NR, Lee KH.

Electrophoresis. 2012 Jul;33(13):1975-9. doi: 10.1002/elps.201100660.

12.

A pilot study of quantitative MRI measurements of ventricular volume and cortical atrophy for the differential diagnosis of normal pressure hydrocephalus.

Moore DW, Kovanlikaya I, Heier LA, Raj A, Huang C, Chu KW, Relkin NR.

Neurol Res Int. 2012;2012:718150. doi: 10.1155/2012/718150. Epub 2011 Aug 7.

13.

Postshunt cognitive and functional improvement in idiopathic normal pressure hydrocephalus.

Katzen H, Ravdin LD, Assuras S, Heros R, Kaplitt M, Schwartz TH, Fink M, Levin BE, Relkin NR.

Neurosurgery. 2011 Feb;68(2):416-9. doi: 10.1227/NEU.0b013e3181ff9d01.

14.

Upper extremity motor measures of Tap Test response in Normal Pressure Hydrocephalus.

Tsakanikas D, Katzen H, Ravdin LD, Relkin NR.

Clin Neurol Neurosurg. 2009 Nov;111(9):752-7. doi: 10.1016/j.clineuro.2009.07.017. Epub 2009 Aug 31.

PMID:
19720451
15.

Disclosure of APOE genotype for risk of Alzheimer's disease.

Green RC, Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Brown T, Eckert SL, Butson M, Sadovnick AD, Quaid KA, Chen C, Cook-Deegan R, Farrer LA; REVEAL Study Group.

N Engl J Med. 2009 Jul 16;361(3):245-54. doi: 10.1056/NEJMoa0809578.

16.

Current state of immunotherapy for Alzheimer's disease.

Relkin NR.

CNS Spectr. 2008 Oct;13(10 Suppl 16):39-41. Review. No abstract available.

PMID:
18955962
17.

Testing the mettle of PBT2 for Alzheimer's disease.

Relkin NR.

Lancet Neurol. 2008 Sep;7(9):762-3. doi: 10.1016/S1474-4422(08)70168-6. Epub 2008 Jul 30. No abstract available.

PMID:
18672401
18.

Features of gait most responsive to tap test in normal pressure hydrocephalus.

Ravdin LD, Katzen HL, Jackson AE, Tsakanikas D, Assuras S, Relkin NR.

Clin Neurol Neurosurg. 2008 May;110(5):455-61. doi: 10.1016/j.clineuro.2008.02.003. Epub 2008 Mar 21.

19.

Incorporating ethnicity into genetic risk assessment for Alzheimer disease: the REVEAL study experience.

Christensen KD, Roberts JS, Royal CD, Fasaye GA, Obisesan T, Cupples LA, Whitehouse PJ, Butson MB, Linnenbringer E, Relkin NR, Farrer L, Cook-Deegan R, Green RC.

Genet Med. 2008 Mar;10(3):207-14. doi: 10.1097/GIM.0b013e318164e4cf.

20.

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.

Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, Younkin S, Younkin L, Schiff R, Weksler ME.

Neurobiol Aging. 2009 Nov;30(11):1728-36. doi: 10.1016/j.neurobiolaging.2007.12.021. Epub 2008 Feb 21.

PMID:
18294736
21.

8-plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease.

Choe L, D'Ascenzo M, Relkin NR, Pappin D, Ross P, Williamson B, Guertin S, Pribil P, Lee KH.

Proteomics. 2007 Oct;7(20):3651-60.

22.
23.

Recall of disclosed apolipoprotein E genotype and lifetime risk estimate for Alzheimer's disease: the REVEAL Study.

Eckert SL, Katzen H, Roberts JS, Barber M, Ravdin LD, Relkin NR, Whitehouse PJ, Green RC.

Genet Med. 2006 Dec;8(12):746-51.

PMID:
17172937
24.

Development and testing of a new outcome measure of relationship between patients with Alzheimer's disease and their partners.

Reilly MC, Relkin NR, Zbrozek AS.

Am J Alzheimers Dis Other Demen. 2006 Aug-Sep;21(4):249-57.

PMID:
16948289
25.

Alzheimer's disease cerebrospinal fluid biomarker discovery: a proteomics approach.

D'Ascenzo M, Relkin NR, Lee KH.

Curr Opin Mol Ther. 2005 Dec;7(6):557-64. Review.

PMID:
16372405
26.

Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study.

Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Green RC; REVEAL (Risk Evaluation and Education for Alzheimer's Disease) Study Group.

J Geriatr Psychiatry Neurol. 2005 Dec;18(4):250-5.

PMID:
16306249
27.

The immune system, amyloid-beta peptide, and Alzheimer's disease.

Weksler ME, Gouras G, Relkin NR, Szabo P.

Immunol Rev. 2005 Jun;205:244-56. Review.

PMID:
15882358
28.

Genetic susceptibility testing versus family history-based risk assessment: Impact on perceived risk of Alzheimer disease.

LaRusse S, Roberts JS, Marteau TM, Katzen H, Linnenbringer EL, Barber M, Whitehouse P, Quaid K, Brown T, Green RC, Relkin NR.

Genet Med. 2005 Jan;7(1):48-53.

PMID:
15654228
29.

Who seeks genetic susceptibility testing for Alzheimer's disease? Findings from a multisite, randomized clinical trial.

Roberts JS, Barber M, Brown TM, Cupples LA, Farrer LA, LaRusse SA, Post SG, Quaid KA, Ravdin LD, Relkin NR, Sadovnick AD, Whitehouse PJ, Woodard JL, Green RC.

Genet Med. 2004 Jul-Aug;6(4):197-203.

PMID:
15266207
30.

Letter and semantic fluency in older adults: effects of mild depressive symptoms and age-stratified normative data.

Ravdin LD, Katzen HL, Agrawal P, Relkin NR.

Clin Neuropsychol. 2003 May;17(2):195-202.

PMID:
13680426
31.

A large, community-based, open-label trial of donepezil in the treatment of Alzheimer's disease.

Relkin NR, Reichman WE, Orazem J, McRae T.

Dement Geriatr Cogn Disord. 2003;16(1):15-24.

PMID:
12714795
32.

Assessment of cognitive recovery following sports related head trauma in boxers.

Ravdin LD, Barr WB, Jordan B, Lathan WE, Relkin NR.

Clin J Sport Med. 2003 Jan;13(1):21-7.

PMID:
12544160
33.

An integrated functional magnetic resonance imaging procedure for preoperative mapping of cortical areas associated with tactile, motor, language, and visual functions.

Hirsch J, Ruge MI, Kim KH, Correa DD, Victor JD, Relkin NR, Labar DR, Krol G, Bilsky MH, Souweidane MM, DeAngelis LM, Gutin PH.

Neurosurgery. 2000 Sep;47(3):711-21; discussion 721-2.

PMID:
10981759
34.

Lower cognitive performance of older football players possessing apolipoprotein E epsilon4.

Kutner KC, Erlanger DM, Tsai J, Jordan B, Relkin NR.

Neurosurgery. 2000 Sep;47(3):651-7; discussion 657-8.

PMID:
10981753
35.

Concordance between functional magnetic resonance imaging and intraoperative language mapping.

Ruge MI, Victor J, Hosain S, Correa DD, Relkin NR, Tabar V, Brennan C, Gutin PH, Hirsch J.

Stereotact Funct Neurosurg. 1999;72(2-4):95-102.

PMID:
10853058
36.

Visual function and brain organization in non-decussating retinal-fugal fibre syndrome.

Victor JD, Apkarian P, Hirsch J, Conte MM, Packard M, Relkin NR, Kim KH, Shapley RM.

Cereb Cortex. 2000 Jan;10(1):2-22.

PMID:
10639391
37.

Intraneuronal Abeta42 accumulation in human brain.

Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR.

Am J Pathol. 2000 Jan;156(1):15-20.

38.

Modulation by DLST of the genetic risk of Alzheimer's disease in a very elderly population.

Sheu KF, Brown AM, Haroutunian V, Kristal BS, Thaler H, Lesser M, Kalaria RN, Relkin NR, Mohs RC, Lilius L, Lannfelt L, Blass JP.

Ann Neurol. 1999 Jan;45(1):48-53.

PMID:
9894876
39.

Promise and peril: new genetic discoveries and Alzheimer disease.

Relkin NR.

Alzheimer Dis Assoc Disord. 1998;12 Suppl 3:S1-2. No abstract available.

PMID:
9876935
40.

Generation and regulation of beta-amyloid peptide variants by neurons.

Gouras GK, Xu H, Jovanovic JN, Buxbaum JD, Wang R, Greengard P, Relkin NR, Gandy S.

J Neurochem. 1998 Nov;71(5):1920-5.

41.

Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides.

Xu H, Gouras GK, Greenfield JP, Vincent B, Naslund J, Mazzarelli L, Fried G, Jovanovic JN, Seeger M, Relkin NR, Liao F, Checler F, Buxbaum JD, Chait BT, Thinakaran G, Sisodia SS, Wang R, Greengard P, Gandy S.

Nat Med. 1998 Apr;4(4):447-51.

PMID:
9546791
42.

Distinct cortical areas associated with native and second languages.

Kim KH, Relkin NR, Lee KM, Hirsch J.

Nature. 1997 Jul 10;388(6638):171-4.

PMID:
9217156
43.

Apolipoprotein E epsilon4 associated with chronic traumatic brain injury in boxing.

Jordan BD, Relkin NR, Ravdin LD, Jacobs AR, Bennett A, Gandy S.

JAMA. 1997 Jul 9;278(2):136-40.

PMID:
9214529
44.

The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective.

Post SG, Whitehouse PJ, Binstock RH, Bird TD, Eckert SK, Farrer LA, Fleck LM, Gaines AD, Juengst ET, Karlinsky H, Miles S, Murray TH, Quaid KA, Relkin NR, Roses AD, St George-Hyslop PH, Sachs GA, Steinbock B, Truschke EF, Zinn AB.

JAMA. 1997 Mar 12;277(10):832-6. Review.

PMID:
9052715
45.

Increased apolipoprotein E epsilon 4 in epilepsy with senile plaques.

Gouras GK, Relkin NR, Sweeney D, Munoz DG, Mackenzie IR, Gandy S.

Ann Neurol. 1997 Mar;41(3):402-4.

PMID:
9066363
46.

NIA/AIzA Conference on apolipoprotein E genotyping in Alzheimer's disease. Bibliography.

Kwon YJ, Tsai J, Relkin NR.

Ann N Y Acad Sci. 1996 Dec 16;802:177-224. No abstract available.

PMID:
9012315
47.
48.

Apolipoprotein E, A beta-amyloid, and the molecular pathology of Alzheimer's disease. Therapeutic implications.

Kaplitt M, Gouras GK, Makimura H, Jovanovic J, Sweeney D, Greengard P, Relkin NR, Gandy S.

Ann N Y Acad Sci. 1996 Dec 16;802:42-9. No abstract available.

PMID:
8993483
49.

Decreased senile plaque density in Alzheimer neocortex adjacent to an omental transposition.

Relkin NR, Edgar MA, Gouras GK, Gandy SE, Goldsmith HS.

Neurol Res. 1996 Aug;18(4):291-4; discussion 295-6.

PMID:
8875444
50.

Apolipoprotein E epsilon 4 and fatal cerebral amyloid angiopathy associated with dementia pugilistica.

Jordan BD, Kanik AB, Horwich MS, Sweeney D, Relkin NR, Petito CK, Gandy S.

Ann Neurol. 1995 Oct;38(4):698-9. No abstract available.

PMID:
7574475

Supplemental Content

Loading ...
Support Center